Opinion

Video

Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer

Author(s):

Stephen J. Freedland, MD,Eleni Efstathiou, MD, PhD

Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer.

  1. Dr. Efstathiou asks Dr. Freedland:Let's start by discussing the importance of early intervention in castration-sensitive prostate cancer (CSPC). What are the potential benefits of treating patients earlier in their disease course?
    1. How does early intervention impact long-term outcomes and quality of life?
    2. What are the risks of delaying systematic treatment?
  2. Dr. Freedland asks Dr. Efstathiou: Discuss the significance of biomarker and genetic testing, as well as imaging, in diagnosis of patients with prostate cancer.
    1. Briefly review guidelines for testing (NCCN Guidelines, Prostate Cancer)
    2. How do these results impact patient management? (eg, prognosis, risk stratification, treatment selection)
Related Videos
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

David Parkinson, MD, president, chief executive officer, ESSA
November 1st 2024

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Bradley C. Carthon, MD, PhD
October 30th 2024

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
October 30th 2024

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer